Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on July 23, 2018. The registrant is incorporated in Delaware and identifies as an emerging growth company. The report addresses a specific corporate governance event rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a personnel change and does not contain financial statements or operational metrics.
Material Changes
The material change reported is the departure of a director:
- Resignation: Roderick MacKinnon resigned as a director of Flex Pharma, Inc., effective July 23, 2018.
- Reason: The resignation was due to Mr. MacKinnon's desire to pursue other interests.
- Disagreement: The filing explicitly states the resignation did not result from any disagreement with the Company.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future operations, or discussion of risks and contingencies beyond the standard disclosure of the director's departure.
Investor Verification Checklist
- Verify the correct registrant name is Flex Pharma, Inc., not Decoy Therapeutics Inc.
- Confirm the effective date of Roderick MacKinnon's resignation (July 23, 2018).
- Review subsequent filings to determine if a replacement director was appointed.
- Check the Company's most recent 10-K or 10-Q for actual financial performance data, as this 8-K contains none.